Rasio utang jangka cendhak marang ekuitas: Coya Therapeutics (COYA)

Coya Therapeutics, Inc. (COYA) maintains a high reputation for developing T-regulatory cell-based therapies to combat ALS. The business model relies on outsourcing production to third-party contractors under strict supervision. This chart shows the market price reaching 0.00, which correlates with successes in treating Alzheimer's disease, patent protection, and potential interest from global pharmaceutical behemoths.

Utilizing external CDMO partners to scale biologics in the US allows Coya Therapeutics, Inc. (COYA) to optimize capital expenditures by minimizing the need for long-term loans. This indicator measures the proportion of short-term liabilities relative to equity, reflecting current liquidity and the balance sheet's reliance on quick loans, which is clearly evidenced by the trend in the short-term debt-to-equity ratio.